Simpler Grants.gov #359168

NIH Forecasted Funding for SenNet Stage 2 Technology Projects

This opportunity is a forecasted funding announcement from the National Institutes of Health (NIH) for Stage 2 of the Cellular Senescence Network (SenNet) Program. - Government Buyer: - National Institutes of Health (NIH) - Includes the Common Fund, National Institute on Aging, National Cancer Institute, and other NIH Institutes and Centers - Program Focus: - Supports research and technology development to advance understanding of senescent cell heterogeneity in health and disease - Seeks innovative tools and technologies for identifying, characterizing, and targeting senescent cells in vivo - Emphasis on Senescence Technology Projects (SenTecs) - Funding Details: - Estimated total funding: $6,000,000 - Up to 15 awards anticipated - Utilizes the UG3/UH3 cooperative agreement mechanism - Eligibility: - Open to nonprofits, tribal organizations, government entities, businesses, and educational institutions - Products/Services: - No specific products, part numbers, or OEMs are listed, as this is a grant forecast for research and technology development - Notable Requirements: - Focus on development of new technologies and tools for in vivo senescent cell analysis - Projects should address senescent cell heterogeneity and its role in health and disease

Description

The NIH Common Fund, National Institute on Aging, National Cancer Institute, and additional NIH Institutes and Centers intend to publish a Notice of Funding Opportunity (NOFO) for Stage 2 of the Cellular Senescence Network (SenNet) Program. The program aims to understand the biological consequences of senescent cell heterogeneity in health and disease and to develop innovative tools and technologies for identifying, characterizing, and targeting senescent cells in vivo. Applications are not currently being solicited; this notice allows potential applicants time to develop collaborations and responsive projects. The NOFO will use the UG3/UH3 activity code and encourages investigators with expertise in cellular senescence and related technologies to apply when the opportunity opens.

View original listing